• RSV is a leading cause of severe respiratory illness in infants, young children, and older adults, resulting in significant hospitalization rates and substantial healthcare costs worldwide.
• Currently, only a limited number of commercial RSV vaccines are available, all of which are administered intramuscularly and approved exclusively for adults; there is no approved RSV vaccine for general pediatric use.
• Existing vaccines do not provide comprehensive protection against RSV infection in the upper respiratory tract and cannot prevent community transmission, highlighting the ongoing lack of safe and effective vaccines or preventive therapies for all vulnerable populations.

• Built on the vaccine platform proven to be safe and effective
• Inducing strong neutralizing antibody
• Easy to use (no need injection)
• Protection in both upper and lower respiratory tract
• Potential to prevent viral transmission

Nasal Spray RSV vaccine

• Animal testing completed
• Open to licensing and collaboration
• US Provisional Application No. 63/723,993
• PCT Application to be filed shortly.